- Han Boter, junior researcher (h.boter@azu.nl)1,
- Johannes J M van Delden, professor of medical ethics2,
- Rob J de Haan, professor of clinical epidemiology3,
- Gabriël J E Rinkel, professor of neurology1
- 1Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands
- 2Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht
- 3Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, Netherlands
- Correspondence to: H Boter
- Accepted 19 May 2003
How do you obtain a valid assessment of subjective outcomes in a trial in which the participants cannot be blinded to the intervention? Bias is inevitable from unblinded patients, but trials that have not told patients about treatment in all arms have been heavily criticised. Asking participants to consent to postponed information could be a solution
The most powerful tool for studying the effectiveness of a medical treatment is a randomised controlled clinical trial with blinded assessment of outcomes. However, blinding is not always possible—for example, in a trial comparing a surgical intervention with non-surgical treatment or the effectiveness of supplemental care compared with conventional care. Blinding needs special attention in such studies in order to prevent bias. When outcomes are assessed by doctors, it is often easy for the assessment to be done by doctors other than those who performed the procedure. However, when studies measure patients' assessment of outcomes, blinding is much more complicated or even impossible.

Credit: PETER GRAY
Dealing with unblinded participants
Unblinded patients who assess outcomes after being informed about the different treatment options during recruitment might bias the results of a study. The likelihood of bias increases when patients have a preference for one of the treatment options. For example, patients may have been told during recruitment that the new or supplemental strategy has been developed because the current strategy has disadvantages. The best way to obtain valid assessments in such studies remains unclear.
Intense debate was generated when researchers tried to mask patients …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012